A new way of treating acute patients in hospital settings with the fast-acting antidepressant treatment, TMS (Transcranial Magnetic Stimulation), has recently gained FDA approval in the United
September 21 is World Alzheimer's Day. Although our knowledge about the causes of Alzheimer's remains limited and no curative treatments are available, several interventions have been proposed to try
Suicide is the leading cause of death amongst young people. According to recent statistics from the World Health Organization (WHO), someone dies from suicide every 40 seconds, which amounts to
Our training courses are designed to instruct clinicians, academics and researchers in the use of neuromodulation technology, with a goal to apply these techniques in clinical practices or research settings. Under the guidance of our expert trainers, students receive substantial hands-on experience with rTMS, tDCS and neurofeedback technology and its application. Over the last 10 years we have trained more than 1,000 professionals from over 30 countries in the use of neuromodulation techniques. We have continually received outstanding feedback from our trainees, with an average evaluation of 8.9/10.
For more than ten years the neuroConn brand has been associated with practice-oriented medical technology used in neuroscience and clinical research, as well as in the diagnosis and treatment of neuropsychological disorders. In close cooperation with leading research institutions and clinics worldwide, neuroConn technology is designed following the latest medical research standards. In this way we provide users with standardised and clinically evaluated protocols in transcranial Electrical Stimulation (tDCS, tACS, tRNS) as well as Neurofeedback of Slow Cortical Potentials.
